drugset / Trial / NCT00919204
Axitinib Pharmacokinetics in Chinese Healthy Volunteers
Non-randomizedSingle-groupOpen-label
Summary
As part of the global clinical development program for AG-013736, studies are ongoing (and planned) in cancer patients in China. An assessment of AG-013736 pharmacokinetics in Chinese subjects, as required by the Chinese Health Authorities, is therefore warranted. In the current study the single dose pharmacokinetics of AG-013736 will be characterized at 3 doses (5 mg, 7 mg and 10 mg).
Timeline
- Start
- 2009-08
- Primary completion
- 2009-08
- Completion
- 2009-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Axitinib | Small molecule | 5 mg | Oral |
| Subject | Axitinib | Small molecule | 7 mg | Oral |
| Subject | Axitinib | Small molecule | 10 mg | Oral |
Indications
No indication recorded.